Investigating Internalization of Reporter-Protein-Functionalized Polyhedrin Particles by Brain Immune Cells

Achieving sustained drug delivery to the central nervous system (CNS) is a major challenge for neurological injury and disease, and various delivery vehicles are being developed to achieve this. Self-assembling polyhedrin crystals (POlyhedrin Delivery System; PODS) are being exploited for the delivery of therapeutic protein cargo, with demonstrated efficacy in vivo. However, to establish the utility of PODS for neural applications, their handling by neural immune cells (microglia) must be documented, as these cells process and degrade many biomaterials, often preventing therapeutic efficacy. Here, primary mouse cortical microglia were cultured with a GFP-functionalized PODS for 24 h. Cell counts, cell morphology and Iba1 expression were all unaltered in treated cultures, indicating a lack of acute toxicity or microglial activation. Microglia exhibited internalisation of the PODS, with both cytosolic and perinuclear localisation. No evidence of adverse effects on cellular morphology was observed. Overall, 20-40% of microglia exhibited uptake of the PODS, but extracellular/non-internalised PODS were routinely present after 24 h, suggesting that extracellular drug delivery may persist for at least 24 h.

A multicellular, neuro-mimetic model to study nanoparticle uptake in cells of the central nervous system

Evaluating the uptake and handling of biomedically relevant nanoparticles by cells of the nervous system critically underpins the effective use of nanoparticle platforms for neuro-regenerative therapies. The lack of biologically relevant and 'neuromimetic' models for nanomaterials testing (that can simulate the cellular complexity of neural tissue) currently represents a bottleneck. Further, propagation of individual cell types, in different neural cell-specific media (as commonly occurs in the nanotechnology field), can result in non-standardised corona formation around particles, confounding analyses of intercellular differences between neural cells in nanoparticle uptake. To address these challenges, we have developed a facile multicellular model that broadly simulates the ratios of neurons, astrocytes and oligodendrocytes found in vivo. All cell types in the model are derived from a single neural stem cell source, and propagated in the same medium overcoming the issue of variant corona formation. Using a fluorescent transfection-grade magnetic particle (MP), we demonstrate dramatic differences in particle uptake and resultant gene transfer between neural cell subtypes, with astrocytes being the dominant population in terms of particle uptake and transfection. We demonstrate the compatibility of the model with a high resolution scanning electron microscopy technique, allowing for membrane features of MP stimulated cells to be examined. Using this approach, astrocytes displayed high membrane activity in line with extensive particle uptake/transfection, relative to neurons and oligodendrocytes. We consider that the stem cell based model described here can provide a simple and versatile tool to evaluate interactions of neural cells with nanoparticle systems developed for neurological applications. Models of greater complexity can be evolved from this basic system, to further enhance its neuromimetic capacity.

Magnetic nanoparticles for oligodendrocyte precursor cell transplantation therapies: progress and challenges

Oligodendrocyte precursor cells (OPCs) have shown high promise as a transplant population to promote regeneration in the central nervous system, specifically, for the production of myelin - the protective sheath around nerve fibers. While clinical trials for these cells have commenced in some areas, there are currently key barriers to the translation of neural cell therapies. These include the ability to (a) image transplant populations in vivo; (b) genetically engineer transplant cells to augment their repair potential; and (c) safely target cells to sites of pathology. Here, we review the evidence that magnetic nanoparticles (MNPs) are a 'multifunctional nanoplatform' that can aid in safely addressing these translational challenges in neural cell/OPC therapy: by facilitating real-time and post-mortem assessment of transplant cell biodistribution, and biomolecule delivery to transplant cells, as well as non-invasive 'magnetic cell targeting' to injury sites by application of high gradient fields. We identify key issues relating to the standardization and reporting of physicochemical and biological data in the field; we consider that it will be essential to systematically address these issues in order to fully evaluate the utility of the MNP platform for neural cell transplantation, and to develop efficacious neurocompatible particles for translational applications.